HIV Diagnostics and Vaccines: It Takes Two to Tango

Colón W.; Oriol-Mathieu V.; Hural J.; Hattingh L.; Adungo F.; Lagatie O.; Lavreys L.; Allen M.; Anzala O.; Espy N.; Fransen K.; Garcia P.J.; Maciel M., Jr.; Murtagh M.; Peel S.A.; Peeling R.W.; Tan L.L.J.; Warren M.; Pau M.G.; D'Souza P.M. · Journal of Infectious Diseases (2024) · DOI: 10.1093/infdis/jiae113

Resumen

Current serologic tests for HIV screening and confirmation of infection present challenges to the adoption of HIV vaccines. The detection of vaccine-induced HIV-1 antibodies in the absence of HIV-1 infection, referred to as vaccine-induced seropositivity/ seroreactivity, confounds the interpretation of test results, causing misclassification of HIV-1 status with potential affiliated stigmatization. For HIV vaccines to be widely adopted with high community confidence and uptake, tests are needed that are agnostic to the vaccination status of tested individuals (ie, positive only for true HIV-1 infection). Successful development and deployment of such tests will require HIV vaccine developers to work in concert with diagnostic developers. Such tests will need to match today’s high-performance standards (accuracy, cost-effectiveness, simplicity) for use in vaccinated and unvaccinated populations, especially in low- and middle-income countries with high HIV burden. Herein, we discuss the challenges and strategies for developing modified serologic HIV tests for concurrent deployment with HIV vaccines. © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved.

Instituciones: Universidad Peruana Cayetano Heredia